Addiction

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Retrieved on: 
Wednesday, January 3, 2024
Other Health, Research, General Health, Cannabis, Pharmaceutical, Mental Health, Natural Resources, Clinical Trials, Science, Biotechnology, Other Science, Health, IND, HTR, Depression, Mouse, Human, Addiction, Anxiety, Hallucination, Artificial intelligence, Concentration ratio, Therapy, DMT, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided an update on data underpinning the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.
  • 5-HT2A is the key receptor correlated to the neuroplastogenic activity of this emerging class of novel drugs.
  • 5-HT1A is a known important therapeutic target because other, already-approved medications for neuropsychiatric indications are known to bind this receptor.
  • HTR is a rodent behavioral model used to predict whether a molecule is likely to produce hallucinogenic effects in humans.

Inspiring True Stories about the Journey from Felon to Faithful

Retrieved on: 
Wednesday, January 3, 2024
Addiction, Hardship, Lord, Forgiveness, Darkness, Abuse, Woman, Scribe, Food, Entertainment

PHOENIX, Jan. 3, 2024 /PRNewswire-PRWeb/ -- Dedicating more than 20 years to ministry, Norman O. Christianson, Scribe has opened his doors to women who have endured hardship, helping them to overcome their past. He shares some of their stories in "The Fourth Watch: A Woman's Journey."

Key Points: 
  • He shares some of their stories in "The Fourth Watch: A Woman's Journey."
  • Christianson shares how he and his wife, Elizabeth, have spent the 20 years ministering to women who have suffered from addiction, abuse, or have been incarcerated.
  • All the stories shared in "The Fourth Watch" are true, shared with Christianson by the women who experienced them.
  • In addition to the stories of the women he has helped, Christianson also shares some stories of his own.

Syra Health Wraps Up a Successful 2023, including New Contracts, Contract Extensions, and the introduction of new Healthcare Innovations

Retrieved on: 
Tuesday, January 2, 2024
Radiology, Addiction, MDHS, City, Health equity, Federation, Mental health, Public health, Expansion, Human services, REACH, Osawatomie State Hospital, Community health, E&I, Nursing, IPO, County, Hospital, Mental, Family, Prison, EMR

Within its Behavioral and Mental Health Business Unit, Syra Health:

Key Points: 
  • Within its Behavioral and Mental Health Business Unit, Syra Health:
    Launched Syrenity, the Company's flagship mental and behavioral product, focused on preventing mental health crises.
  • Secured a five-year, $4.75 million contract with the District of Columbia's Department of Behavioral Health, to support vital mental health programs in communities.
  • Across its Digital Health Business Unit, Syra Health:
    Launched CarePlus, an easy-to-use, secure, and scalable electronic medical record (EMR) system for small and mid-sized healthcare organizations.
  • "2023 was a transformative year for Syra Health," said Dr. Deepika Vuppalanchi, CEO, Syra Health.

God Extends Forgiveness Regardless of Actions, Identities and Current Circumstances

Retrieved on: 
Tuesday, January 2, 2024
Failure, Xulon Press, Reader, Motivation, Bird, Multimedia, Wind, Pain, Mariners Church, CHEF, Okinawan, Cooking, Forgiveness, Trauma, Knowledge, Singing, Face, Addiction, Salem Media Group, Imperial Noble Consort, Teaching, Nature, Amazon, Life, Book

NEWPORT BEACH, Calif. , Jan. 2, 2024 /PRNewswire-PRWeb/ -- Author Fabrice Poigin aims to help readers looking for personal growth and a relationship with God in THE HUNGER WITHIN: A CHEF'S PROFOUND JOURNEY THROUGH HIS WORLD ($20.49, paperback, 9781662888656; $8.99, e-book, 9781662888663).

Key Points: 
  • Writing about one's inner struggles can be a cathartic process and a way to make sense of personal challenges.
  • Fabrice Poigin, a world travelled French Chef, penned this creatively written, thought-provoking book to help men of all ages savor the nourishing bread of life.
  • Poigin, who himself, has faced personal struggles with addiction, has sought assistance and knowledge in this area, leading to his own healing journey.
  • He now takes what he has experienced and provides readers with the ultimate reality that God stands ready to extend forgiveness to his followers, regardless of one's actions, identity, or current life circumstances.

Rotary Action Group Taps Drug Free Australia to Represent Oceania on a Global Stage

Retrieved on: 
Sunday, December 24, 2023
Health promotion, Policy, RAG, Partnership, Organization, AP, Addiction, Government, Drug

Seaford, Australia, Dec 24, 2023 - (ACN Newswire) - Drug Free Australia has been selected by the Rotary Action Group for Addiction Prevention (RAG AP) to represent the Oceania region.

Key Points: 
  • Seaford, Australia, Dec 24, 2023 - (ACN Newswire) - Drug Free Australia has been selected by the Rotary Action Group for Addiction Prevention (RAG AP) to represent the Oceania region.
  • As a leader in drug prevention, Drug Free Australia will collaborate with international organizations to address pressing drug-related challenges in Oceania.
  • This collaboration between Drug Free Australia and RAG AP is poised to address drug use concerns in Oceania significantly.
  • Furthermore, Drug Free Australia will leverage its resources and networks to bolster drug prevention efforts across Oceania.

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Retrieved on: 
Friday, December 29, 2023
Mental Health, Health, Other Health, Other Science, Science, Biotechnology, Sale, Depression, Roth Capital Partners, Form, Addiction, Anxiety, Form S-3, Therapy, Security (finance), Exercise

The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1.8 million, before deducting financial advisory fees.

Key Points: 
  • The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $1.8 million, before deducting financial advisory fees.
  • The reduction of the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules.
  • The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-3 (File No.
  • The securities offered in the private placement have not been registered under the Securities Act, or applicable under state securities laws.

Rotary Action Group Taps Drug Free Australia to Represent Oceania on a Global Stage

Retrieved on: 
Sunday, December 24, 2023
Health promotion, Policy, RAG, Partnership, Organization, AP, Addiction, Government, Drug

Seaford, Australia--(Newsfile Corp. - December 23, 2023) - Drug Free Australia has been selected by the Rotary Action Group for Addiction Prevention (RAG AP) to represent the Oceania region.

Key Points: 
  • Seaford, Australia--(Newsfile Corp. - December 23, 2023) - Drug Free Australia has been selected by the Rotary Action Group for Addiction Prevention (RAG AP) to represent the Oceania region.
  • As a leader in drug prevention, Drug Free Australia will collaborate with international organizations to address pressing drug-related challenges in Oceania.
  • This collaboration between Drug Free Australia and RAG AP is poised to address drug use concerns in Oceania significantly.
  • Furthermore, Drug Free Australia will leverage its resources and networks to bolster drug prevention efforts across Oceania.

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

Retrieved on: 
Monday, December 18, 2023
MYIG, MAR, Depression, FDA, Research, Psilocybin, Patent, Addiction, LSD, Mental health, Anxiety, ADHD, OTC, Therapy, Fibrosis, DMT, Pharmaceutical industry

This Composition of Matter patent underscores Mydecine's commitment to innovation in mental health therapeutics.

Key Points: 
  • This Composition of Matter patent underscores Mydecine's commitment to innovation in mental health therapeutics.
  • MYCO-005 is designed with selective binding to 5-HT2A receptors and does not bind to 5-HT2B receptors for both macro and microdosing.
  • In 2020, Mydecine filed its provisional patent application encompassing multiple families of psilocin analogs, with MYCO-005 emerging as a second-generation breakthrough.
  • Mydecine Innovations Group continues to lead the way in biotechnological advancements, dedicated to pioneering safer and more effective solutions for mental health and addiction disorders.

Webinar to Highlight Impact of Opioid Crisis on Vulnerable Populations

Retrieved on: 
Monday, December 4, 2023
Drug, Treatment, Mental health, Addiction, Government, Heroin, Partnership, Fentanyl, Deafness, Strategic planning, Prohibition, Human services, COVID-19, Social policy, New Jersey State Police, Advertising, Hard, Organization, Consumer protection, Hearing, Communication, Pharmaceutical industry

The webinar, “The Opioid Epidemic: A Focus on Vulnerable Populations,” which is the third to focus on vulnerable populations, will be held at 11 a.m. Thursday, December 7.

Key Points: 
  • The webinar, “The Opioid Epidemic: A Focus on Vulnerable Populations,” which is the third to focus on vulnerable populations, will be held at 11 a.m. Thursday, December 7.
  • “It is important to understand why vulnerable populations exist and work to help them access the resources and aid they need as we continue to experience the devastating impact of the opioid crisis.”
    The webinar will be the 11th in the 2023 Knock Out Opioid Abuse Day Learning Series.
  • The Knock Out Opioid Abuse Day Learning Series began in 2020 during the COVID-19 pandemic to educate New Jersey residents on various aspects of the opioid epidemic and its impact on New Jersey and the nation.
  • To learn more about Knock Out Opioid Abuse Day and for a schedule of webinars, please visit knockoutday.drugfreenj.org .

Recovery First Treatment Center Announces Second Community Talk on Forgiveness and Reconciliation in Recovery

Retrieved on: 
Monday, November 20, 2023
Forgiveness, Family, Addiction, Friends, Depression, Hope, Anxiety, Social isolation, Communication

HOLLYWOOD, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Recovery First Treatment Center, a leading provider of substance use treatment services in South Florida, is hosting an upcoming community talk on the topic of "Moving Beyond the Past: Forgiveness and Reconciliation in Recovery."

Key Points: 
  • HOLLYWOOD, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Recovery First Treatment Center, a leading provider of substance use treatment services in South Florida, is hosting an upcoming community talk on the topic of "Moving Beyond the Past: Forgiveness and Reconciliation in Recovery."
  • To address these issues, the live webinar will focus on the importance of forgiveness and reconciliation in the recovery process.
  • The upcoming talk will be held on November 21 at 6 pm ET with Recovery First’s Clinical Director, Dr. Jesus Perez.
  • To address these issues, the webinar will focus on the power of forgiveness and reconciliation in the recovery process.